BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
316.05
+9.03 (2.94%)
At close: Dec 19, 2025, 4:00 PM EST
317.97
+1.92 (0.61%)
After-hours: Dec 19, 2025, 7:32 PM EST
BeOne Medicines AG Employees
BeOne Medicines AG had 11,000 employees as of December 31, 2024. The number of employees increased by 400 or 3.77% compared to the previous year.
Employees
11,000
Change (1Y)
400
Growth (1Y)
3.77%
Revenue / Employee
$452,062
Profits / Employee
$6,232
Market Cap
34.97B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11,000 | 400 | 3.77% |
| Dec 31, 2023 | 10,600 | 1,600 | 17.78% |
| Dec 31, 2022 | 9,000 | 1,000 | 12.50% |
| Dec 31, 2021 | 8,000 | 2,700 | 50.94% |
| Dec 31, 2020 | 5,300 | 1,800 | 51.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ONC News
- 1 day ago - BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma - Business Wire
- 9 days ago - Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors - PRNewsWire
- 11 days ago - BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia - Business Wire
- 12 days ago - Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies - Business Wire
- 15 days ago - BeOne Medicines Continues To Execute In Q3 - Seeking Alpha
- 23 days ago - Artisan International Small-Mid Fund Q3 2025 Performance Review - Seeking Alpha
- 23 days ago - U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma - Business Wire
- 4 weeks ago - BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025 - Business Wire